A randomized, placebo-controlled trial of d-cycloserine for the enhancement of social skills training in autism spectrum disorders

Table 2 Sample characteristics at enrollment across sites

Characteristics	Cincinnati (n=15)	Indiana University (n=52)	p-value
Demographics
Age (years), mean (SD)	8.56 (1.77)	8.24 (1.84)	.56
Sex, n (%) male	11 (73.33)	44 (84.62)	.44^a
Group, n (%) Cycloserine	8 (53.33)	26 (50.00)	.82
Clinical Variables
Stanford-Binet V, mean (SD)
Full Scale IQ	87.86 (13.78)	90.40 (17.67)	.62
NonVerbal IQ	92.57 (15.36)	93.10 (17.17)	.92
Verbal IQ	85.29 (14.19)	88.92 (18.94)	.51
VABS-II Expressive Language subscale standard score, mean (SD)	84.67 (9.76)	86.37 (15.21)	.68
Clinical Global Impression-Severity	4.00 (0.00)	4.06 (0.24)	.38
Diagnosis, n (%)
PDD-NOS	9 (60.00)	18 (34.62)	.08
Autistic Disorder	4 (26.67)	4 (7.69)	.07^a
Asperger’s Disorder	2 (13.33)	30 (57.69)	.003^a*
Concomitant medications, n (%)
Antipsychotics	2 (13.33)	14 (26.92)	.49^a
Alpha-2 Agonists	3 (20.00)	11 (21.15)	1.00^a
Stimulants	8 (53.33)	17 (32.69)	.15
Sleep Aids	3 (20.00)	13 (25.00)	1.00^a
Mood Stabilizers	0 (0.00)	3 (5.77)	1.00^a
Glutamatergic Modulators	0 (0.00)	1 (1.92)	1.00^a
Other	1 (6.67)	3 (5.77)	1.00^a
Concomitant treatment, n (%)
Speech Therapy	6 (40.00)	30 (57.69)	.23
Occupational Therapy	6 (40.00)	21 (40.38)	.98
Behavioral Therapy	2 (13.33)	16 (30.77)	.32^a
Other Psychotherapy	0 (0.00)	3 (5.77)	1.00^a
Physical Therapy	1 (6.67)	1 (1.92)	.40^a
Social Skills Training	1 (6.67)	4 (7.69)	1.00^a
Music Therapy	1 (6.67)	0 (0.00)	.22^a
Other Treatments	1 (6.67)	2 (3.85)	.54^a

ISSN: 2040-2392